GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Ozempic and Mounjaro's side effects have a few similar side effects as the NHS plans to rollout the jab for weight loss ...

Nick Carter ’s recent slim-down has caused a stir among his fans, but a source exclusively tells Us Weekly that he’s not on ...

Amid fears over her worrying appearance, Katie Price’s home life is slipping into even more chaos. Read more on Closer online ...

From broccoli to booze to Brie, nothing makes presidents seem more like regular people than the arbitrary and utterly personal list of foods they had banned from the White House. Strong winds broke ...

Comparing pictures of the 45-year-old boybander from 2022 to now seem to suggest he's taking a trendy GLP-1 agonist drug ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

WITH Mounjaro users shedding nearly double the amount of weight compared to its other counterparts, it’s no wonder the ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Jeremy Clarkson rolls up the leg of his suit trousers to show me his pickleball injuries. It’s not pretty: a blackened area ...